Adalimumab in recalcitrant severe psoriasis associated with atopic dermatitis

Case Reports in Dermatology
Savas YayliN Yawalkar

Abstract

Tumor necrosis factor-α inhibitors may induce various cutaneous side effects including eczematous-like lesions. The management of such side effects can be challenging. Herein, we report a case of a 55-year-old man who had a flare-up and subsequent improvement of atopic dermatitis during treatment of severe psoriasis with adalimumab.

Citations

Aug 5, 2015·Journal of Clinical Medicine·Andrea Montes-TorresJavier Sánchez-Pérez
Sep 10, 2014·Expert Opinion on Investigational Drugs·Kristina Sophie Ibler, Gregor Be Jemec
Apr 14, 2012·International Immunopharmacology·Jun SunJinhong Hu
Aug 30, 2016·The Journal of Dermatological Treatment·Mio NakamuraTina Bhutani
Jul 25, 2017·International Journal of Dermatology·Martin Havmose, Simon Francis Thomsen
Jan 31, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·A Al-JanabiR B Warren
Sep 2, 2017·Archivum Immunologiae Et Therapiae Experimentalis·Katarzyna OsinkaWojciech Feleszko
Jun 4, 2019·Journal of the American Academy of Dermatology·Maria C SchneeweissJoseph F Merola

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.